How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/moderate-to-severe-atopic-dermatitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

moderate-to-severe atopic dermatitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

moderate-to-severe atopic dermatitis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating moderate-to-severe atopic dermatitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ebglyss	LEBRIKIZUMAB	Eli Lilly And Co	Interleukin-13 Antagonist [EPC]		2025-01-01
Adbry	TRALOKINUMAB	Leo Pharma As	Interleukin-13 Antagonist [EPC]	Interleukin-13	2021-01-01
Abrocitinib Suspension F2	abrocitinib-suspension-f2	Pfizer	unknown	unknown
Induction- PF-06480605 450 mg SC Q4W	induction-pf-06480605-450-mg-sc-q4w	Pfizer	small molecule	IL-17 receptor
Chronic- PF-06480605 150 mg SC Q4W	chronic-pf-06480605-150-mg-sc-q4w	Pfizer	Janus kinase inhibitor	JAK1 and JAK2 enzymes
Chronic- PF-06480605 450 mg SC Q4W	chronic-pf-06480605-450-mg-sc-q4w	Pfizer	pharmacological class not specified	IL-4 receptor alpha subunit
Chronic- PF-06480605 50 mg SC Q4W	chronic-pf-06480605-50-mg-sc-q4w	Pfizer	JAK inhibitor	JAK pathway
Induction- PF-06480605 150 mg SC Q4W	induction-pf-06480605-150-mg-sc-q4w	Pfizer	JAK inhibitor	JAK pathway

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 6 drugs in moderate-to-severe atopic dermatitis
Eli Lilly And Co · 1 drug in moderate-to-severe atopic dermatitis
Leo Pharma As · 1 drug in moderate-to-severe atopic dermatitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in moderate-to-severe atopic dermatitis:

Cite this brief

Drug Landscape (2026). moderate-to-severe atopic dermatitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moderate-to-severe-atopic-dermatitis. Accessed 2026-06-10.

moderate-to-severe atopic dermatitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing